XBIO - The Buzz Show: Xenetic Biosciences Inc (NASDAQ: XBIO) USD 12.5 Million Private Stock Sale

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Xenetic Biosciences Inc Surges Amid $12.5 Million Private Stock Sale”

Xenetic Biosciences Inc (NASDAQ: XBIO) climbed over 29% in premarket trading after the company announced a 12.5 million dollar private placement with a single healthcare-focused institutional investor.

The purchase of 4,629,630 shares of the company’s common stock at a price per share of $2.70 also comes with an agreement to issue to the investor warrants to purchase up to 4,629,630 shares of common stock at an exercise price of $3.30 per share.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART , a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

For more information, please visit: Xenetic Biosciences Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Xenetic Biosciences Inc (NASDAQ: XBIO) USD 12.5 Million Private Stock Sale first appeared on Financial Buzz .

For further details see: